Cathie Wood的ARK ETF资本以Coinbase（Coin）和Robinhood（Hood）股票的回调资本

输入：Cathie Wood的ARK ETFS资本以Coinbase（Coin）和Robinhood（Hood）股票的回调资源为

Cathie Wood's ARK ETFs on Thursday capitalized on the pullback in Coinbase (NASDAQ:COIN) and Robinhood (NASDAQ:HOOD) stocks to load up additional shares.

凯茜·伍德（Cathie Wood）的ARK ETF周四大利用Coinbase（NASDAQ：COIN）和Robinhood（NASDAQ：HOOD）股票的回调，以加载额外的股票。

The ARK Innovation Fund (ARKK) bought 29,353 new shares of Coinbase at $191.8 per share for a total of $5.63 million. The move comes following Coinbase's exclusion from the S&P 500 Index (SPX) and the broader weakness in the crypto markets.

ARK Innovation Fund（ARKK）以每​​股191.8美元的价格购买了29,353股Coinbase的新股，总计563万美元。此举是在Coinbase排除在标准普尔500指数（SPX）和加密市场中更广泛的弱点之后的。

Coinbase shares are trading lower by 58% year-to-date and down 64% over the past 12 months. At current levels, analysts see 68% potential downside.

在过去的12个月中，Coinbase股票的交易额降低了58％，下降了64％。在目前的水平上，分析师看到68％的潜在缺点。

Earlier this week, ARKK ETF had acquired 52,573 shares of the crypto platform, and the ARK Fintech Innovation ETF (ARKF) bought 11,605 shares.

本周早些时候，ARKK ETF收购了Crypto平台的52,573股，ARK Fintech Innovation ETF（ARKF）购买了11,605股。

Another notable trade made yesterday was the purchase of 143,855 shares of Robinhood Markets (NASDAQ:HOOD) at $39.07 per share for a total of $5.6 million. Earlier this week, the ARKK ETF purchased 269,864 shares of HOOD stock.

昨天进行的另一个值得注意的交易是购买143,855股Robinhood Markets（NASDAQ：HOOD），每股39.07美元，总计560万美元。本周早些时候，ARKK ETF购买了269,864股Hood股票。

Additionally, the ARKK ETF and the ARK Genomic Revolution ETF (ARKG) bought a total of 105,974 CRISPR Therapeutics (NASDAQ:CRSP) shares for $4.6 million and 80,975 GitLab (NASDAQ:GITL) shares for $4.27 million.

此外，ARKK ETF和ARK Genomic Revolution ETF（ARKG）以460万美元和80,975 Gitlab（NASDAQ：GITL）的股份以42.7万美元的价格购买了105,974 CRISPR Therapeutics（NASDAQ：CRSP）股票。

Which Cathie Wood Pick Is Rated a ‘Strong Buy’ by Wall Street?

华尔街被评为“强劲买”的凯茜木片？

Using TipRanks’ Stock Comparison Tool, let's see what Wall Street thinks of Cathie Wood's stock picks.

使用Tipranks的库存比较工具，让我们看看华尔街对Cathie Wood的股票选秀的看法。

Out of the four stocks, GitLab stock has a Strong Buy consensus rating among analysts.

在四个股票中，Gitlab股票在分析师之间的共识评级很高。

CRISPR Therapeutics shares have a Hold rating with seven Buys, 14 Holds, and two Sells. The average CRISPR stock price target of $37.34 suggests about 22% downside potential.

CRISPR Therapeutics股票的评级为七个购买，14个持有和2个卖出。 CRISPR股票目标价为37.34美元，表明下行潜力约为22％。

Cathie Wood Dumps PATH Stock

Cathie Wood倾倒路径库存

Cathie Wood's ARK ETFs on Thursday reduced their exposure to UiPath (NYSE:PATH) stock as her ARK Next Generation Internet ETF (ARKW) sold 900,000 shares of the automation software company.

Cathie Wood的ARK ETF周四减少了他们对Uipath（NYSE：PATH）股票的接触，因为她的方舟下一代Internet ETF（ARKW）出售了90万股自动化软件公司的股票。

The move follows the recently reported mixed Q4 results and soft guidance from UiPath.

此举遵循最近报道的Q4结果和Uipath的软指导。

The reduced exposure comes after a period of increased investment in UiPath. Earlier this week, the ARKK ETF plowed $10 million into UiPath stock.

在对Uipath的投资增加之后，暴露量减少。本周早些时候，ARKK ETF向Uipath股票耕种了1000万美元。

According to the SEC filing, the ARKK ETF and the ARKW ETF collectively sold 1,101,216 shares of PATH stock for $13 million.

根据SEC文件，ARKK ETF和ARKW ETF共同出售了1,101,216股Path Stock，售价为1300万美元。

The sell-off in UiPath stock is part of a broader trend in Cathie Wood's ARK ETFs, which have been selling off some of their largest holdings in recent months.

Uipath股票的抛售是Cathie Wood的ARK ETF的更广泛趋势的一部分，Cathie Wood的ARK ETF近几个月来一直出售其最大的持股。

This sell-off comes amid macro uncertainties and tariff wars that are dragging down crypto markets and U.S. stocks. However, some of the deepest cuts in U.S. stocks over the past 12 months make them attractive bargain picks.

这种抛售是出于宏观不确定性和关税战争而拖延加密市场和美国股票的原因。但是，在过去的12个月中，美国股票中一些最深的削减使它们有吸引力的讨价还价。

See more PATH analyst ratings

查看更多路径分析师评分